BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20150329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20151025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20161030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160510
DTEND;VALUE=DATE:20160515
DTSTAMP:20160426T132317Z
CREATED:20160426T131842Z
LAST-MODIFIED:20160426T132317Z
UID:15292-1462838400-1463270399@ces.b2sg.org
SUMMARY:The Biology of Genomes
DESCRIPTION:The 29th annual meeting on The Biology of Genomes will begin at 7:30 pm on Tuesday\, May 10\, 2016 and run through lunch on Saturday\, May 14. \nThe 2016 meeting will address DNA sequence variation and its role in molecular evolution\, population genetics and complex diseases\, comparative genomics\, large-scale studies of gene and protein expression\, and genomic approaches to ecological systems. Both technologies and applications will be emphasized. In addition there will be a special session on the ethical\, legal and social implications (ELSI) of genome research. \n\nTopics:\n\n\nTranslational Genomics & Genetics\nGenetics of Complex Traits\nCancer & Medical Genomics\nFunctional Genomics\nComputational Genomics\nEvolutionary & Non-Human Genomics\nPopulation Genomics\n\n\nKeynote Speakers:\nEmmanuelle Charpentier\, Max Planck Institute for Infection Biology\, Germany\nNeil Shubin\, University of Chicago
URL:https://ces.b2sg.org/event/the-biology-of-genomes/
LOCATION:Cold Spring Harbor Laboratory\, 1 Bungtown Road\, Cold Spring Harbor\, NY\, 11724-2213\, United States
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/CSH.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160509
DTEND;VALUE=DATE:20160514
DTSTAMP:20160425T175531Z
CREATED:20160425T145654Z
LAST-MODIFIED:20160425T175531Z
UID:15270-1462752000-1463183999@ces.b2sg.org
SUMMARY:Cold Spring Harbor Asia: Chromatin\, Epigenetics and Transcription
DESCRIPTION:We are pleased to announce the 4th Cold Spring Harbor Asia conference on Chromatin\, Epigenetics and Transcription which will be held in Suzhou\, China\, located approximately 60 miles west of Shanghai. The conference will begin at 7:00pm on the evening of Monday May 9\, and will conclude after lunch on May 13\, 2016. \nThe conference will include eight oral sessions and one poster session covering the latest findings across many topics in Epigenetics. Many talks will be selected from the openly submitted abstracts on the basis of scientific merit and relevance. Social events throughout the conference provide ample opportunity for informal interactions.
URL:https://ces.b2sg.org/event/cold-spring-harbor-asia-chromation-epigenetics-and-transcription/
LOCATION:Suzhou Dushu Lake Conference Center\, No.299 Qiyue Road\, Suzhou\, Jiangsu Province\, China
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/Chromatin-Epigenetics-and-Transkription.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160506
DTEND;VALUE=DATE:20160507
DTSTAMP:20160419T151535Z
CREATED:20160419T013938Z
LAST-MODIFIED:20160419T151535Z
UID:14909-1462492800-1462579199@ces.b2sg.org
SUMMARY:Ann Schreiber Mentored Investigator Award
DESCRIPTION:The Ann Schreiber Mentored Investigator Award (formerly the Ann Schreiber Research Training Programs of Excellence Award) provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must be clinical fellows (Gynecologic Oncology\, Medical Oncology)\, or post-doctoral fellows. Candidates for this program must have an MD or a PhD degree. This grant is named in honor of Ann Schreiber\, in whose memory OCRF was founded. \nDuration of funding: 1-2 years \nCoverd costs:  £75\,000 annually \nNationality: US
URL:https://ces.b2sg.org/event/ann-schreiber-mentored-investigator-award/
LOCATION:AZ
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/ocrf.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160506
DTEND;VALUE=DATE:20160507
DTSTAMP:20160419T151148Z
CREATED:20160419T013809Z
LAST-MODIFIED:20160419T151148Z
UID:14907-1462492800-1462579199@ces.b2sg.org
SUMMARY:Liz Tilberis Early Career Award
DESCRIPTION:Launched in December 2000\, the Liz Tilberis Early Career Award (formerly called the Liz Tilberis Scholars Award) is for junior faculty with a strong commitment to an investigative career in ovarian cancer research. These awards support a substantial time commitment to research and academic endeavors in ovarian cancer. \nDuration of funding: 3 years \nCoverd costs:  £150\,000 annually \nNationality: US
URL:https://ces.b2sg.org/event/liz-tilberis-early-career-award/
LOCATION:AZ
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/ocrf.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160506
DTEND;VALUE=DATE:20160507
DTSTAMP:20160419T150806Z
CREATED:20160419T013545Z
LAST-MODIFIED:20160419T150806Z
UID:14905-1462492800-1462579199@ces.b2sg.org
SUMMARY:Collaborative Research Development Grant
DESCRIPTION:Launched in 2004\, this research program provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions. The grant is for investigators seeking to develop program project grant applications for submission to peer-review funding agencies (e.g. NCI\, RO1\, SPORE\, DOD). \nDuration: 3 years \nCovered costs:$300\,000 annually \nNationality: US
URL:https://ces.b2sg.org/event/collaborative-research-development-grant-formerly-named-program-project-development-grant/
LOCATION:AZ
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/ocrf.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160506
DTEND;VALUE=DATE:20160507
DTSTAMP:20160419T160750Z
CREATED:20160419T013028Z
LAST-MODIFIED:20160419T160750Z
UID:14898-1462492800-1462579199@ces.b2sg.org
SUMMARY:Program Project Development Grant
DESCRIPTION:This research program provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions. The grant is for investigators seeking to develop program project grant applications for submission to peer-review funding agencies (e.g. NCI\, RO1\, SPORE\, DOD). \nDuration of funding: 3 years \nCovered costs: $300000 \nNationality: US
URL:https://ces.b2sg.org/event/program-project-development-grant/
LOCATION:AZ
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160503
DTEND;VALUE=DATE:20160508
DTSTAMP:20160426T154441Z
CREATED:20160426T154441Z
LAST-MODIFIED:20160426T154441Z
UID:15307-1462233600-1462665599@ces.b2sg.org
SUMMARY:Nuclear Organization & Function
DESCRIPTION:You are cordially invited to participate in the ninth meeting on Nuclear Organization and Function\, which will be held at Cold Spring Harbor Laboratory. The meeting will begin on the evening of Tuesday\, May 3\, 2016\, and will conclude with lunch on Saturday\, May 7. The specific goal for this meeting is to bring together cellular and molecular biologists to discuss recent advances in the spatial and temporal aspects of nuclear structure/function. \n\nTopics:\n\n\nChromatin Organization\nBiology of Nuclear RNAs\nTranscription\nThe Nuclear Membrane & Nuclear Lamina\nNucleocytoplasmic Transport\nEpigenetics\nGene Expression\nNuclear Functions in Development & Disease\n\n\n\nDiscussion Leaders:\nMartin Beck\, European Molecular Biology Laboratory\, Germany\nWendy Bickmore\, MRC Human Genetics Unit\, UK\nJob Dekker\, University of Massachusetts Medical School\nPeter Fraser\, Babraham Institute\, UK\nJoseph Gall\, Carnegie Institution for Science\nRobert Goldman\, Feinberg School of Medicine\, Northwestern University\nDaniel Larson\, National Cancer Institute\nJohn Lis\, Cornell University\nMatthias Merkenschlager\, Imperial College London\, UK\nTom Misteli\, National Cancer Institute\nKathrin Plath\, University of California Los Angeles\nYaron Shav-Tal\, Bar-Ilan University\, Israel\nJane Skok\, New York University School of Medicine\nAngela Taddei\, Institut Curie/CNRS\, France\nSusan Wente\, Vanderbilt University Medical Center\nYixian Zheng\, Carnegie Institution for Science \n\nThe format of the meeting will include oral sessions consisting of two 15-minute anchoring talks by the discussion leaders and seven 12-minute talks\, selected from the abstracts\, principally on unpublished work. In addition\, there will be two poster sessions\, one in the afternoon and one in the evening. The organizers will decide the suitability of each abstract for oral or poster presentation\, but please specify if you prefer a poster. \nAbstracts should contain only new and unpublished material and must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentation will be made by the organizers and individual session chairs. Status (talk/poster) of abstracts will be posted on our web site as soon as decisions have been made by the organizers. \nWe are eager to have as many young people as possible attend since they are likely to benefit most from this meeting. We have applied for funds from government and industry to partially support graduate students and postdocs. Apply in writing to Val Pakaluk stating need for financial support – preference is given to those submitting abstracts. \nAll questions pertaining to registration\, fees\, housing\, meals\, transportation\, visas\, abstract submission or any other matters should be directed to Val Pakaluk \nWe look forward to seeing you at Cold Spring Harbor in May.
URL:https://ces.b2sg.org/event/nuclear-organization-function/
LOCATION:Cold Spring Harbor Laboratory\, 1 Bungtown Road\, Cold Spring Harbor\, NY\, 11724-2213\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/CSH.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160502
DTEND;VALUE=DATE:20160503
DTSTAMP:20160419T160654Z
CREATED:20160419T012133Z
LAST-MODIFIED:20160419T160654Z
UID:14892-1462147200-1462233599@ces.b2sg.org
SUMMARY:Catalyst Grants
DESCRIPTION:Breast Cancer Now is the UK’s leading breast cancer research charity. They believe research is what will ultimately give women with breast cancer more time to live. Their goal: by the year 2050\, no one dies from this disease. \nIn order to reach this goal they have launched a new funding initiative called “Breast Cancer Now Catalyst Programme”. It is meant to bring bring together Europe’s leading breast cancer researchers and the world’s leading pharmaceutical companies to pool resources and stop women dying from breast cancer. \nTheir partner Pfizer provides substantial funding for research grant as well as access to a number of its licensed and investigational drugs that may be useful for treating breast cancer. \nBreast Cancer Now will use its peer review process to decide which research projects will be supported and will have access to Pfizer’s drugs. Pfizer will not be involved in making the decisions about which projects are funded. \nDuration of funding: – \nCovered costs:  £300\,000 for a single research question and may be based at one or multiple sites and £1 million in total for studies of exceptional potential (address a range of questions around a common theme\, or undertake research using several of the Pfizer drugs\, or multi-centre phase II clinical studies) \nNationalities: Europe
URL:https://ces.b2sg.org/event/catalyst-grants/
LOCATION:AZ
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160501
DTEND;VALUE=DATE:20160506
DTSTAMP:20160419T160436Z
CREATED:20151230T044905Z
LAST-MODIFIED:20160419T160436Z
UID:12192-1462060800-1462492799@ces.b2sg.org
SUMMARY:Epigenetic and Metabolic Regulation of Aging and Aging-Related Diseases
DESCRIPTION:Meeting Summary \nAging poses formidable scientific\, medical and societal challenges. Old age is the single most important risk factor for a constellation of diseases\, including cardiovascular disease\, cancer\, diabetes and a range of neurodegenerative disorders such as Alzheimer’s disease. Aging is also one of the greatest fundamental mysteries in biology\, and arguably its next frontier. Long thought to be inexorable\, aging has in fact been shown to be malleable due to specific changes in genes or environment. This Keystone Symposia meeting will cover the most exciting questions at the forefront of the field: How can external stimuli delay aging in a long-lasting\, yet reversible\, manner? Does the integration of external stimuli to modulate aging differ among cells with vastly diverse functions – somatic maintenance\, tissue regeneration and the “immortal” germline? Is aging a synchronous process\, and how do the different cells and systems communicate? How do diseases of aging develop\, and what can be done to prevent or reverse them? To address these questions\, the symposium will gather investigators from completely different areas to bring an interdisciplinary approach to aging. The meeting will focus on the emerging nexus between two key aging regulators – epigenetic states of the genome and metabolic status – and will highlight innovative technologies and the newest discoveries in aging and diseases. This symposium will also address questions from different perspectives\, taking advantage of model organisms with drastically divergent lifespans and aging strategies. Importantly\, this meeting will particularly discuss human aging and its associated traits – frailty\, susceptibility to diseases – and potential aging therapeutics.
URL:https://ces.b2sg.org/event/epigenetic-and-metabolic-regulation-of-aging-and-aging-related-diseases/
LOCATION:Hilton Santa Fe Historic Plaza Hotel\, Santa Fe\, NM\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160429
DTEND;VALUE=DATE:20160430
DTSTAMP:20160419T155753Z
CREATED:20160419T011244Z
LAST-MODIFIED:20160419T155753Z
UID:14882-1461888000-1461974399@ces.b2sg.org
SUMMARY:The search for the best cancer research in the world
DESCRIPTION:Since 1979 “worldwide cancer research” has invested into nearly two thousand reseach projects all over the world. The goal of this grant is to support research that might in future help reduce the incidence of cancer or improve cancer survial. \nGrants are awarded to support fudamental or translational research into the causes\, mechanisms\, diagnosis\, treatment or prevention of cancer. \nDuration of funding: 1-3years \nCovered costs: direct costs of conducting the research \nNationality: international
URL:https://ces.b2sg.org/event/the-search-for-the-best-cancer-research-in-the-world/
LOCATION:AZ
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/worldwide-cancer-research1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160424
DTEND;VALUE=DATE:20160429
DTSTAMP:20160419T160331Z
CREATED:20151230T044602Z
LAST-MODIFIED:20160419T160331Z
UID:12189-1461456000-1461887999@ces.b2sg.org
SUMMARY:Game of Epigenomics
DESCRIPTION:The ‘Game of Epigenomics’ conference will celebrate the great diversity in the epigenomics field\, reflecting both on DNA and protein modifications. The conference will host international and national leaders in the field\, covering the spectrum of epigenomic research\, presenting data from diverse model systems as well as clinical research and new insights in disease epigenomics. The conference will move from basic epigenetic mechanisms and chromatin structure\, epigenomics and epigenomic technologies to clinical and translational epigenetics. \nThe historic town of Dubrovnik will play host to an Epigenomics conference for the first time. Also\, the conference will mark the closure of the InnoMol project\, and will enable a final brainstorming of InnoMol partnering institutions\, but also give an opportunity for new networking between world class scientists during our Game of Epigenomics. \nThus\, we will create an atmosphere with cutting edge science highlighting the latest developments in the epigenomics field\, support extensive scientific discussions\, and ample possibilities for socializing\, networking and also exploring the remarkable surrounds. Picturesque Dubrovnik\, host town of the world famous TV show ‘Game of Thrones’ is situated on the very South of Croatia. Surrounded by crystal clear Adriatic sea it is also known as the Pearl of Dalmatia.
URL:https://ces.b2sg.org/event/game-of-epigenomics/
LOCATION:Unnamed Venue\, Dubrovnik\, Croatia (Local Name: Hrvatska)
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/game-of-epigenetics.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160419
DTEND;VALUE=DATE:20160423
DTSTAMP:20160419T155206Z
CREATED:20151230T044217Z
LAST-MODIFIED:20160419T155206Z
UID:12186-1461024000-1461369599@ces.b2sg.org
SUMMARY:3rd Annual Epigenetic  Inhibitor Discovery  - Targeting Histone Methyltransferases\, Demethylases and Bromodomains
DESCRIPTION:Targeting epigenetic modifiers and readers\, particularly histone methyltransferases\, demethylases and bromodomain-containing proteins have recently set the foundation for a new generation of anti-cancer drugs. Over the past few years\, several companies have developed and successfully moved novel compounds targeting EZH2\, DOT1L\, LSD1\, and a collection of BET bromodomain inhibitors into clinical studies. As these compounds continue to progress\, developers are now focused on the discovery of new targets and designing novel inhibitors to expand into this robust target space. Of particular interest for discovery are non-BET bromodomain proteins and methyl lysine readers; arginine methyltransferases; and JmjC-domain containing demethylases. \nCambridge Healthtech Institute will once again convene leaders in Epigenetic Inhibitor Discovery to bring forth novel and emerging strategies for inhibition\, new bioactive tools and inhibitors\, as well as strategies for lead optimization to obtain clinically relevant small molecules.
URL:https://ces.b2sg.org/event/3th-annual-epigenetic-inhibitor-discovery-targeting-histone-methyltransferases-demethylases-and-bromodomains/
LOCATION:Hilton San Diego Resort and Spa\, San Diego\, CA\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/crop-drug.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160408
DTEND;VALUE=DATE:20160409
DTSTAMP:20160111T211359Z
CREATED:20151218T191804Z
LAST-MODIFIED:20160111T211359Z
UID:11958-1460073600-1460159999@ces.b2sg.org
SUMMARY:Ruth L- Kirschstein National Research service F30 Award
DESCRIPTION:The NCI Ruth L. Kirschstein National Research service F30 Award supports promising doctoral candidates who will perform dissertation research and training for an MD/PhD degree in a scientific health-related field relevant to the mission of the NCI during the tenure of the award. Applicants for the F30 must be within 48 months of matriculation into an accredited MD/PhD program at the time of application. \nNCI requires a clear cancer focus in graduate research training and gives funding priority to applications whose primary sponsor has cancer-related R01 or R01-like\, peer-reviewed research grants at the time of application and the time of the award. For the NCI F30 Award\, R01-like research funding includes peer-reviewed research grants from other federal sources and private foundations with a duration of at least 3 years with a minimum of $150\,000 direct costs per year. The primary sponsor is expected to maintain such grant support during the project period. Grants under a no-cost extension do not qualify. \nReminder to NCI Fellowship grantees: Changes in the Project\nIndividual fellowship awards are made for training at a specific institution under the guidance of a particular sponsor. Prior approval by NCI is required for a transfer of the award to another institution\, a change in sponsor\, or a significant project change. If the primary sponsor plans to be absent for a continuous period of more than 3 months\, an interim sponsor must be named by the institution and approved in writing by NCI.
URL:https://ces.b2sg.org/event/ruth-l-kirschstein-national-research-service-f30-award/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/NCI.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160320
DTEND;VALUE=DATE:20160325
DTSTAMP:20160105T214319Z
CREATED:20151222T211132Z
LAST-MODIFIED:20160105T214319Z
UID:11995-1458432000-1458863999@ces.b2sg.org
SUMMARY:Chromatin and Epigenetics
DESCRIPTION:Meeting Summary\n\nThe DNA of eukaryotic cells is organized into chromatin fibers\, where the nucleosome is the basic repeating unit. Chromatin is thus at the core of fundamental processes such as gene regulation\, stem cell fate determination and cancer. By and large\, these topics have traditionally been covered by separated meetings. However\, recent literature indicates that the boundaries among these various disciplines are becoming less clear. This meeting will bring together scientists studying chromatin structure\, epigenetics\, stem cell biology and cancer. The talks will cover a broad range of topics\, including chromosome organization\, long-range interactions\, chromatin assembly\, stem cell regulation/differentiation\, RNA-based mechanisms and transcription regulation. Speakers have been selected to broadly reflect lessons learned from a variety of model organisms and experimental approaches. Young scientists will be able to present their work through a large number of short talks selected from submitted abstracts as well as through poster presentation. There will also be ample time for exchanging ideas and discussing novel hypothesis at the end of each session\, as well as time for informal interactions and networking.
URL:https://ces.b2sg.org/event/chromatin-and-epigenetics/
LOCATION:Whistler Conference Centre\, Whistler\, British Columbia\, Canada\, Whistler\, BC\, Canada
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160317
DTEND;VALUE=DATE:20160320
DTSTAMP:20160105T200320Z
CREATED:20151222T210452Z
LAST-MODIFIED:20160105T200320Z
UID:11991-1458172800-1458431999@ces.b2sg.org
SUMMARY:Epigenetic Regulation of Skin Regeneration \, Ageing and Disease
DESCRIPTION:Dear Colleagues\,\nOn behalf of the Organizing Committee\, I am delighted to announce our International Symposium “Epigenetic Regulation of Skin Regeneration\, Ageing and Disease”\, which we will organize in Bradford on March 17th-19th\, 2016. \nEpigenetics Symposium Flyer \nThe idea of the Symposium is to bring skin and chromatin biologists together and further promote the epigenetic research in skin biology and dermatology\, as well as to introduce the skin as an excellent model for epigenetic research to chromatin biologists. \nA highlight of the event will be the John Wood Memorial Lecture Award to Professor Elaine Fuchs from Rockefeller University who will deliver a lecture on “Epigenetic mechanisms controlling skin stem cell activity” \nJoining Instructions \nRegistration\, Programme details and Abstract submission forms are available from the respective tabs to the left. \nWe welcome all researchers interested in skin epigenetics to attend the Symposium and enhance your knowledge in this exciting and rapidly emerging area of modern science! \nOur First International Symposium “Epigenetic Control of Skin Development and Regeneration” organized in Bradford in 2012 was highly successful and attracted over 90 researchers from the UK\, Europe\, USA\, Japan\, Australia and Singapore. This time\, the Symposium will cover both basic and translational aspects epigenetic research including epigenetic control of skin ageing\, wound healing and inflammation. \nWe look forward to welcoming you to Bradford next year…..on behalf of the Organizing Committee \nProf. Vladimir Botchkarev \nDeputy Director of the Centre for Skin Sciences \nUniversity of Bradford
URL:https://ces.b2sg.org/event/epigenetic-regulation-of-skin-regeneration-ageing-and-disease/
LOCATION:Bradford University\, Bradford\, United Kingdom
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/free-vector-university-of-bradford_051314_university-of-bradford.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160303
DTEND;VALUE=DATE:20160305
DTSTAMP:20160105T214825Z
CREATED:20151222T204608Z
LAST-MODIFIED:20160105T214825Z
UID:11988-1456963200-1457135999@ces.b2sg.org
SUMMARY:6th Clinical Epigenetics International meeting
DESCRIPTION:This 2-day conference will focus on the study of epigenetic changes in normal and diseased cells in response to internal or external factors with the aim to translate basic epigenetic research into diagnosis\, therapy and prevention.
URL:https://ces.b2sg.org/event/6th-clinical-epigenetics-international-meeting/
LOCATION:Jugendherberge Düsseldorf City-Hostel \, Düsseldorf Str. 1\, D-40545\, Düsseödorf\, North Rhine-Westphalia\, 40210-40629\, Germany
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/clepso.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160221
DTEND;VALUE=DATE:20160225
DTSTAMP:20160105T214226Z
CREATED:20151218T174323Z
LAST-MODIFIED:20160105T214226Z
UID:11938-1456012800-1456358399@ces.b2sg.org
SUMMARY:Noncoding RNA in Health and Disease
DESCRIPTION:Meeting Summary\n\nOver the past decade\, there has been a greater understanding of genomic complexity in eukaryotes ushered in by the immense technological advances in high-throughput sequencing of DNA and its corresponding RNA transcripts. This has resulted in the realization that beyond protein-coding genes\, there are a large number of transcripts that do not encode for proteins and\, therefore\, may perform their function through RNA sequences and/or through secondary and tertiary structural determinants. This Keystone Symposia meeting is focused on the latest findings concerning different classes of noncoding RNAs that use different strategies to regulate transcription. These are exciting times for discovering the biological scope and the mechanism of action for these RNA molecules\, which have roles in dosage compensation\, imprinting\, enhancer function and transcriptional regulation\, with a consequently great impact in development and disease.
URL:https://ces.b2sg.org/event/noncoding-rna-in-health-and-disease/
LOCATION:Unnamed Venue\, Santa Fe\, NM\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160217
DTEND;VALUE=DATE:20160218
DTSTAMP:20160111T213040Z
CREATED:20151218T171741Z
LAST-MODIFIED:20160111T213040Z
UID:11927-1455667200-1455753599@ces.b2sg.org
SUMMARY:Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
DESCRIPTION:Purpose: to advance research in cancer etiology and early detection biomarkers\, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate\, Lung\, Colorectal\, and Ovarian Cancer (PLCO) Screening Trial
URL:https://ces.b2sg.org/event/utilizing-the-plco-biospecimens-resource-to-bridge-gaps-in-cancer-etiology-and-early-detection-research-u01-4/
LOCATION:AZ
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/NIH2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T210004Z
CREATED:20151218T191013Z
LAST-MODIFIED:20160111T210004Z
UID:11957-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 7: Deliver biologically active macromolecules to and all cells in the body to effectively treat cancer
DESCRIPTION:In recent years\, scientists have been experimenting with using large molecules called ‘macromolecules’ to target and destroy tumour cells. These macromolecules can disrupt the processes that cancer cells use to survive – for example by stopping them from growing or by flagging their presence to the body’s immune system. \nThis approach works very well on cancer cells in the laboratory\, but unlike conventional ‘small molecule’ treatments like aspirin\, it’s really difficult to deliver these molecules to\, and then into\, the cells where they need to act. \nIf we could work out ways of delivering these macromolecules to any and every cell in the body\, it would not only create a totally new way to treat cancer but would have a huge impact on other diseases too.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-7-deliver-biologically-active-macromolecules-to-and-all-cells-in-the-body-to-effectively-treat-cancer/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205935Z
CREATED:20151218T190515Z
LAST-MODIFIED:20160111T205935Z
UID:11956-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 6:  Develop innovative approaches to target the cancer super-controller MYC
DESCRIPTION:Myc is a gene that is mutated and persistently switched on in the majority of human cancers – it’s a hallmark of the disease in nearly seven out of ten cases. \nMutant and overactive Myc helps tumours survive\, and this strongly suggests that blocking its function would be a powerful approach to treating many types of cancer. \nOf course\, Myc isn’t the only gene mutation that’s linked to cancer\, so why is this a Grand Challenge? It’s partly because the gene makes a protein (called MYC) that is a powerful ‘super controller’–a vital hub at the centre of a vast communication network within cells\, and the properties of the MYC protein itself make it really difficult to design a drug against it. \nThat’s why we’re putting out a call to the global research community – this challenge needs more than just money\, it needs new thinking\, innovation and a wide range of expertise.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-6-develop-innovative-approaches-to-target-the-cancer-super-controller-myc/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205820Z
CREATED:20151218T185901Z
LAST-MODIFIED:20160111T205820Z
UID:11955-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 5: Find a way of mapping tumours at the molecular and cellular level
DESCRIPTION:Cancer cells live in complex communities. Just like houses in a city\, each cell in a tumour is different from its neighbour\, and relies on infrastructure to support its existence. \nThere are different neighbourhoods–some worse than others. Where we have roads\, tumours contain blood vessels that deliver nutrients\, and act as highways for different cell types to move around. And when a tumour spreads\, the cancer cells themselves use these blood ‘roads’ to migrate. \nWhat we really need is a Google Earth-like view of a tumour. If we could make a 3D map\, we’d find new targets for treatment and\, eventually\, could use this view to track what’s going on in real time\, such as in response to treatment.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-5-find-a-way-of-mapping-tumours-at-the-molecular-and-cellular-level/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205731Z
CREATED:20151218T184157Z
LAST-MODIFIED:20160111T205731Z
UID:11954-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 4:  Distinguish between lethal cancers that need treating\, and non-lethal cancers that don’t
DESCRIPTION:It’s a hard concept to imagine\, but not all of the things we call ‘cancer’ need to be treated. Some ‘cancers’ are temporary changes to cells that will reverse or disappear with time\, and others are so slow-growing they’ll never cause any problems. \nFor some cancers\, over-diagnosis leads to unnecessary treatment and avoidable side effects. In others\, we desperately need to be able to detect the disease earlier – but do so in a more accurate way. \nIn lung cancer\, for example\, X-ray scans can’t distinguish between spots where there is nothing to worry about\, or the early stages of an aggressive cancer that needs prompt treatment. \nThis is a Grand Challenge that would both save lives and improve quality of life – for millions of people worldwide.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-4-distinguish-between-lethal-cancers-that-need-treating-and-non-lethal-cancers-that-dont/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205641Z
CREATED:20151218T183659Z
LAST-MODIFIED:20160111T205641Z
UID:11953-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 3: Discover how unusual patterns of mutation are induced by different cancer-causing events
DESCRIPTION:Certain things in the world around us\, such as tobacco smoke\, cause cancer. They do this by triggering chemical changes inside cells\, leading to errors in the reading of the DNA genetic code. \nThe patterns of these DNA changes are different for each cause (or ‘carcinogen’) – almost as if they are signing their names on our genomes – and scientists can identify known carcinogens from their chemical signatures. \nBut there are unusual signatures whose origins we don’t know\, caused in ways we haven’t yet identified. And in cancers caused by factors such as obesity\, there will be many different signatures\, and we don’t yet know how to pick them apart. \nSo in the same way that a detective uses forensic evidence from a crime scene to identify a criminal\, we need to work backwards to find these cancer-causing events\, to prevent the cancers they’re causing.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-3-discover-how-unusual-patterns-of-mutation-are-induced-by-different-cancer-causing-events/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205524Z
CREATED:20151218T182244Z
LAST-MODIFIED:20160111T205524Z
UID:11948-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 2: Eradicate EBV-induced cancers from the world
DESCRIPTION:Around 19 in 20 adults carry the Epstein Barr Virus (EBV)\, making it one of the most common human viral infections. \nIn most people\, EBV is relatively harmless\, although it’s the cause of glandular fever\, “kissing disease”. But in some parts of the world it’s a big problem – every year\, EBV infection accounts for 200\,000 new cases of cancer worldwide\, and more than 140\,000 deaths. \nTo eradicate EBV-induced cancers from the world is a grand challenge that would make a significant difference to global health\, and is a fully achievable ambition.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-2-eradicate-ebv-induced-cancers-from-the-world/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205318Z
CREATED:20151218T181421Z
LAST-MODIFIED:20160111T205318Z
UID:11943-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards - Challenge 1: Develop vaccines to prevent non-viral cancers
DESCRIPTION:Vaccines already exist that prevent cancers caused by infection\, such as against the human papilloma virus that causes some cervical cancers. But this challenge is to develop vaccines that work against non-viral cancers\, which are caused by faults in our DNA that accumulate over time. \nThat’s what really makes this a Grand Challenge. Because cancer is a disease of the body’s own cells\, it is more challenging to coax the immune system to recognize and eliminate early stage cancers\, where the difference between healthy cells and abnormal cells might be very small. \nBut the promise is huge: imagine if we could vaccinate against cancer as we do for infectious diseases such as TB and measles. Grand Challenge could make this a reality.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-1-develop-vaccines-to-prevent-non-viral-cancers/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160119
DTEND;VALUE=DATE:20160120
DTSTAMP:20160111T205520Z
CREATED:20151218T181151Z
LAST-MODIFIED:20160111T205520Z
UID:11944-1453161600-1453247999@ces.b2sg.org
SUMMARY:Research Travel Award
DESCRIPTION:Cancer Research UK seeks to attract the best postdoctoral researchers to perform groundbreaking cancer research. The purpose of the Research Travel Awards is to enable ambitious postdoctoral researchers to visit research groups elsewhere in the UK or overseas to:\nIntroduce new expertise\, techniques or skills to the travelling scientist’s current research group  Establish or develop collaborations between research groups  Develop their own research career with a view to becoming an independent researcher  Attend a skills-based training course  Pursue a cancer-related project if they do not currently work in cancer research\nResearch Travel Awards are considered by the Research Travel Award Panel.
URL:https://ces.b2sg.org/event/research-travel-award/
LOCATION:AZ
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160110
DTEND;VALUE=DATE:20160115
DTSTAMP:20160105T213716Z
CREATED:20151218T173720Z
LAST-MODIFIED:20160105T213716Z
UID:11934-1452384000-1452815999@ces.b2sg.org
SUMMARY:Metabolism\, Transcription and Disease
DESCRIPTION:Meeting Summary\n\nTo maintain homeostasis\, cells need to coordinate gene expression and metabolic state. There is increasing evidence that misregulation of metabolic flux and gene transcription plays a major role in human diseases\, including obesity\, diabetes and cancer. The aim of this meeting is to explore how metabolic state influences gene expression programs and\, conversely\, how intermediary metabolism is controlled by the transcription machinery and chromatin-modulating enzymes. Particular emphasis will be on the connection between gene transcription and metabolism in homeostatic and diseased state. Emerging evidence emphasizes that chromatin-modifying enzymes depend on substrates\, or co-factors\, that are key components of intermediary metabolism. The cellular concentration of these metabolites fluctuates in response to\, for example\, nutrient availability\, circadian cycles or oncogenic transformation. Thus\, chromatin might be considered a sensor of metabolic state. Moreover\, some metabolic enzymes play surprisingly direct roles in transcription control. Conversely\, transcriptional control of metabolic enzyme expression\, for example by nuclear receptors or the oncogene Myc\, plays a major role in maintaining homeostasis\, circadian rhythm or driving cell growth and proliferation. The aim of this Keystone Symposia meeting is to bring together scientists working on basic aspects of transcription control\, epigenetics\, metabolic disease and cancer. The meeting should serve as a discussion platform to explore the rapidly growing interphase between transcription regulation\, metabolic reprogramming and human disease.
URL:https://ces.b2sg.org/event/keystone-symposia-on-molecular-and-cellular-biology-metabolism-transcription-and-disease/
LOCATION:Unnamed Venue\, Snowbird\, UT\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160109
DTSTAMP:20181103T130437Z
CREATED:20151218T172802Z
LAST-MODIFIED:20181103T130437Z
UID:11928-1452124800-1452297599@ces.b2sg.org
SUMMARY:USCAP 108th Annual Meeting: ASCP & ASIP Joint Meeting
DESCRIPTION:Current and Future Revolution in Pathology Practice: (Focus on) Immuno-oncology and Cancer Epigenetics \nASIP/ASCP will bring together 4 speakers from across two unique disciplines of pathology to discuss the practice\, science\, and challenges of immuno-oncology and cancer epigenetics intended to inform and education residents\, fellows\, and practicing pathologists.  The course will begin with a practical discussion of IO in current practice (Mamatha Chivukula\, Sutter Health\, CA) from the perspective of a community-based pathologist. This segment will review the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc.\, with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions. This will be followed up by a discussion of cutting-edge science in the IO space (Mike Milone\, UPenn) with emphasis on those technologies and tools that are likely to move into clinical space soon. This same approach to cancer epigenetics (David Williams\, UNC) will be revealed and discussed in the third presentation. Both of these cutting-edge talks will identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics.  To finish off\, a “future talk” focused on how cancer epigenetics will affect patient care and everyday diagnostics will be presented (Idriss M. Bennani-Baiti\, President\, Cancer Epigenetics Society\, Vienna\, Austria). This portion will assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care. \nCourse Learning Objectives\nUpon completion of this educational activity\, the learner will be able to: \n\nReview the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc. with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions\nIdentify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics\nAssess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care\n\n\nSESSION CHAIRS\n\n\nModerator \nDanny Milner\, MD\, MSc\, ASCP\n\n\n\n\n\nPRESENTATIONS\n\n\n1:30 PM\n1:35 PM\n\n\nIntroduction to the Session and Outline of the Symposium Objectives\n\n\nDanny Milner\, MD\, MSc\nASCP\n\n\n\n\n\n\n\n1:35 PM\n2:10 PM\n\n\n“Immunotherapy” From Bench to Community Practice- Are Pathologists Ready for the #gamechanger?\n\n\nMamatha Chivukula\, MD\, FASCP\nMills-Peninsula Hospital\, Sutter Health Affiliate\n\n\n\n\n\n\n\n2:10 PM\n2:45 PM\n\n\nCutting Edge Science in Immuno-Oncology: Where to next?\n\n\nMichael Milone\, MD\, Phd\nUniversity of Pennsylvania Perelman School of Medicine\n\n\n\n\n\n\n\n2:45 PM\n3:20 PM\n\n\nBreak\n\n\n\n\n\n\n3:20 PM\n3:55 PM\n\n\nFrom DNA Methylation to Chromatin Remodeling\, the Expanding Role of Epigenetic Changes in Cancer Biology\n\n\nDavid Williams\, MD\, PhD\nUniversity of North Carolina at Chapel Hill\n\n\n\n\n\n\n\n3:55 PM\n4:30 PM\n\n\nPractical Epigenetics: How Today’s Cancer Epigenetics Research Will Change the Field of Pathology Tomorrow\n\n\nIdriss Bennani-Baiti\, PhD\nChildren’s Cancer Research Institute Vienna\n\n\n\n\n\n\n\n4:30 PM\n5:00 PM\n\n\nPanel Discussion\n\n\nDanny Milner\, MD\, MSc
URL:https://ces.b2sg.org/event/ascp-asip-joint-meeting/
LOCATION:National Harbor\, Maryland\, Singapore
CATEGORIES:Meetings
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160108
DTSTAMP:20151218T175506Z
CREATED:20151218T174519Z
LAST-MODIFIED:20151218T175506Z
UID:11932-1452124800-1452211199@ces.b2sg.org
SUMMARY:Research Grant Programm
DESCRIPTION:Supports research projects aimed at understanding the causes of breast cancer\, prevention or developing new treatments for metastatic breast cancer
URL:https://ces.b2sg.org/event/research-grant-programm/
LOCATION:AZ
CATEGORIES:Grants
END:VEVENT
END:VCALENDAR